Please assess the completion status of the following clinical trial:

Trial Title: Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known cases of Idiopathic Dilated Cardiomyopathy (IDC)~* Those patients in whom heart failure medications were stable for at least 1 month~* More than 6 months aged~Exclusion Criteria:~* Recent modification in medications~* Hemodynamic instability~* Congenital heart disease~* Metabolic heart disease~* Cardiac dysfunction resulting from abnormalities in other organs and those with an acquired cardiomyopathy

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Coenzyme Q10 (Type: EXPERIMENTAL): Known cases of idiopathic dilated cardiomyopathy who received supplementation of coenzyme Q10 as a part of their medical regimen.~Dosage administered: 2 milligram/kilogram/day in 2 or 3 divided doses, these being increased to the maximum dose of 10 milligram/kilogram/day according to tolerance or the appearance of sideeffects.
- Placebo (Type: PLACEBO_COMPARATOR): known cases of idiopathic dilated cardiomyopathy who received placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).